'Impact of the CABG SYNTAX Score on 10-year All-cause Death: Insights from the SYNTAX Extended Survival Study' by Kuniaki Takahashi et al. #EAPCI bit.ly/3bab1Z5

CircInterventions William Fearon Kuniaki Takahashi Department of Cardiovascular Sciences - KU Leuven

How best to achieve hyperemia in assessment of coronary microvascular function. In-vivo validation of hyperemia #cardiotwitter #AHAJournals William Fearon Kuniaki Takahashi Lennert Minten ahajrnls.org/3UhYKJP

Prospective, multi-center RCT examines one-month #DAPT followed by ticagrelor monotherapy in patients undergoing multivessel #PCI . fal.cn/34xLS #JACC Kuniaki Takahashi

What is the survival prognosis at 10 years in all-comers patients with de novo three-vessel disease or left main #cvCAD randomized to #PCI or #cvCABG who were originally enrolled in the SYNTAX trial? Find out here: bit.ly/3panGTr #CardioTwitter Kuniaki Takahashi

New paper in The Lancet by Kuniaki Takahashi, Dr. David van Klaveren & colleagues: Redevelopment & validation of the SYNTAX score II to predict benefit of CABG vs. PCI over a 10y period for patients w/ complex coronary artery disease. Ewout Steyerberg David M Kent thelancet.com/journals/lance…

Circulation Seth Bilazarian, MD Kuniaki Takahashi David Holmes After all, human beings are only weak people.

If you did not have the chance to read the paper on the redevelopment and validation of the SYNTAX score II by Kuniaki Takahashi David van Klaveren & colleagues yet, it is now available online with free access: authors.elsevier.com/c/1b~m0V-4XAoDq